Clinical trials: CEACAM5
Liver Metastases
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
This is an open label fixed dose phase Ib of anti-CEA CAR-T cells hepatic artery infusions and yttrium-90 SIR-Spheres in patients with CEA-expressing liver metastases.
- Trial name
- HITM-SIR (NCT02416466)
- Testing
- anti-CEA CAR-T cells, Sir-Spheres
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roger Williams Medical Center
Non-small Cell Lung Cancer Metastatic
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Primary Objectives: Study was designed with multiple primary endpoints analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival [PFS] and overall survival [OS]) Study…
- Trial name
- CARMEN-LC03 (NCT04154956)
- Testing
- SAR408701, Docetaxel
- Where
- 169 sites in United States, Argentina and 24 more
- Volunteers
- 389 people
- Sponsor
- Sanofi
Circulating Tumor Cells
Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer
The purpose of the study is to evaluate the association between the number of circulating tumor cells and response to treatment in non small-cell lung cancer patients
- Trial name
- NCT01052818
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- National Institute of Cancerología
Advanced Solid Tumours
A Study of EBC-129 in Advanced Solid Tumours
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
- Trial name
- NCT05701527
- Testing
- EBC-129, Pembrolizumab
- Where
- 5 sites in United States, Singapore and 1 more
- Volunteers
- 98 people
- Sponsor
- EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Pancreas Adenocarcinoma
NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101
Pancreatic carcinoma has a dismal prognosis at time of diagnosis, due to late onset of clinical symptoms, patients present with advance disease.
- Trial name
- FLUOPANC-II (NCT05984810)
- Testing
- Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Colorectal Cancer
Carbohydrate Antigen 19-9 in Colorectal Cancer
4,972 patients who underwent surgery for primary CRC between January 2004 and December 2015 at Seoul National University Hospital were retrospectively reviewed.
- Trial name
- NCT04999072
- Testing
- Colectomy for colon cancer
- Where
- South Korea
- Volunteers
- 4,972 people
- Sponsor
- Seoul National University Hospital
Rectal Neoplasms, Rectum Cancer
SGM-101 in Colorectal Brain Metastases.
This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101…
- Conditions
- Rectal Neoplasms, Rectum Cancer, Colorectal Neoplasms, Brain Metastases
- Trial name
- SGM-CBM (NCT04755920)
- Testing
- SGM-101
- Where
- 2 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Advanced Non-small Cell Lung Cancer, First Line Treatment
Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer
In pre-clinical study we found that the thioredoxin reductase activity of serum harbours huge difference between cancer patients and non-cancer patients, the enzyme activity elevated remarkably among cancer patients, and after…
- Conditions
- Advanced Non-small Cell Lung Cancer, First Line Treatment, Thioredoxin Reductase Activity, Carcinoembryonic Antigen
- Trial name
- NCT01980212
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Hunan Province Tumor Hospital
Pancreatic Cancer
Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer
Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA.
- Trial name
- NCT00003434
- Testing
- carcinoembryonic antigen peptide 1, hepatitis B antigen peptide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Breast Cancer
Immunotherapy in Treating Patients With Metastatic Breast Cancer
RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to and kill their tumor cells.
- Trial name
- NCT00003432
- Testing
- carcinoembryonic antigen RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Lung Cancer
Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis
Lung cancer is the first cause of death among cancer patients. Non Small Cell lung cancer (NSCLS) represents about 80-85% of the cases. Of this, about 80% presents with locally advanced or metastatic disease.
- Trial name
- PCI (NCT01603849)
- Testing
- Prophylactic Cranial Irradiation
- Where
- Mexico
- Volunteers
- 84 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Solid Tumors
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
This is an open-label, multicenter, dose-escalation and expansion Phase Ib clinical study of RO6958688 in combination with atezolizumab. Part I of the study is subdivided into parts IA and IB.
- Trial name
- NCT02650713
- Testing
- Atezolizumab, RO6958688
- Where
- 24 sites in United States, Canada and 5 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Carcinoma (NSCLC), Melanoma
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
The purpose of this study is to evaluate the safety and tolerability of humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 (CM-24 [MK-6018]), administered intravenously as monotherapy and in combination with…
- Conditions
- Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02346955
- Testing
- CM-24 (MK-6018), Pembrolizumab (MK-3475)
- Where
- 3 sites in United States, Israel
- Volunteers
- 27 people
- Sponsor
- Famewave Ltd.
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R
- Trial name
- AMPLIFY-7P (NCT05726864)
- Testing
- ELI-002 7P
- Where
- 28 sites in United States
- Volunteers
- 158 people
- Sponsor
- Elicio Therapeutics
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Non-small Cell Lung Cancer Metastatic
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
Primary Objectives: Doublet Cohort Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of tusamitamab ravtansine in combination with ramucirumab in the NSQ NSCLC population.
- Trial name
- CARMEN-LC04 (NCT04394624)
- Testing
- SAR408701, ramucirumab, pembrolizumab
- Where
- 13 sites in United States, Bulgaria and 4 more
- Volunteers
- 31 people
- Sponsor
- Sanofi
Colorectal Carcinoma Metastatic in the Liver, Metastatic Colorectal Carcinoma
An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer
This phase I trial studies how well an imaging agent called I-124 M5A works in detecting CEA-positive colorectal cancer that has spread to the liver.
- Conditions
- Colorectal Carcinoma Metastatic in the Liver, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8
- Trial name
- NCT03993327
- Testing
- Iodine I 124 Monoclonal Antibody M5A, Positron Emission Tomography
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- City of Hope Medical Center
Advanced Solid Tumor Cancer
Phase II Study of LM-24C5
This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor
- Trial name
- NCT07387081
- Testing
- LM-24C5
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- LaNova Medicines Limited
Metastatic Cancer
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
Background: Carcinoembryonic antigen (CEA) is a protein present mostly in cancer cells. An experimental procedure developed for treating patients with cancer uses blood cells found in their tumors or bloodstream.
- Trial name
- NCT00923806
- Testing
- PG13-CEA_TCR (Anti-CEA TCR PBL), Aldesleukin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
This is an open-label, multi-center, Phase Ib clinical study of cergutuzumab amunaleukin, in combination with atezolizumab, to investigate the safety, pharmacokinetics, and therapeutic activity in participants with locally…
- Trial name
- NCT02350673
- Testing
- Atezolizumab, Cergutuzumab Amunaleukin
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 70 people
- Sponsor
- Hoffmann-La Roche